These findings identify a TKT/c-Myc positive feedback loop that underlies TACE resistance and HCC progression, nominating TKT as a biomarker of refractoriness and a therapeutic target to improve locoregional treatment outcomes. The gene discussed is MYC; the disease is hepatocellular carcinoma.